Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3]. |
In vitro | Terazosin exhibits non-selective activity towards cloned α1-adrenoceptor subtypes transiently expressed in COS cells [1]. |
In vivo | Terazosin facilitates the expulsion of ureteral stones, particularly effective for distal ureteral stones larger than 5 mm [3]. It is recognized as a safe and efficient option for this treatment. |
Molecular Weight | 387.43 |
Formula | C19H25N5O4 |
CAS No. | 63590-64-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Terazosin 63590-64-7 inhibitor inhibit